BACKGROUND: The involvement of the complement system in brain injury has been scarcely investigated. Here, we document the pivotal role of mannose-binding lectin (MBL), one of the recognition molecules of the lectin complement pathway, in brain ischemic injury. METHODS AND RESULTS: Focal cerebral ischemia was induced in mice (by permanent or transient middle cerebral artery occlusion) and rats (by 3-vessel occlusion). We first observed that MBL is deposited on ischemic vessels up to 48 hours after injury and that functional MBL/MBL-associated serine protease 2 complexes are increased. Next, we demonstrated that (1) MBL(-/-) mice are protected from both transient and permanent ischemic injury; (2) Polyman2, the newly synthesized mannosylated molecule selected for its binding to MBL, improves neurological deficits and infarct volume when given up to 24 hours after ischemia in mice; (3) anti-MBL-A antibody improves neurological deficits and infarct volume when given up to 18 hours after ischemia, as assessed after 28 days in rats. CONCLUSIONS: Our data show an important role for MBL in the pathogenesis of brain ischemic injury and provide a strong support to the concept that MBL inhibition may be a relevant therapeutic target in humans, one with a wide therapeutic window of application.
BACKGROUND: The involvement of the complement system in brain injury has been scarcely investigated. Here, we document the pivotal role of mannose-binding lectin (MBL), one of the recognition molecules of the lectin complement pathway, in brain ischemic injury. METHODS AND RESULTS: Focal cerebral ischemia was induced in mice (by permanent or transient middle cerebral artery occlusion) and rats (by 3-vessel occlusion). We first observed that MBL is deposited on ischemic vessels up to 48 hours after injury and that functional MBL/MBL-associated serine protease 2 complexes are increased. Next, we demonstrated that (1) MBL(-/-) mice are protected from both transient and permanent ischemic injury; (2) Polyman2, the newly synthesized mannosylated molecule selected for its binding to MBL, improves neurological deficits and infarct volume when given up to 24 hours after ischemia in mice; (3) anti-MBL-A antibody improves neurological deficits and infarct volume when given up to 18 hours after ischemia, as assessed after 28 days in rats. CONCLUSIONS: Our data show an important role for MBL in the pathogenesis of brain ischemic injury and provide a strong support to the concept that MBL inhibition may be a relevant therapeutic target in humans, one with a wide therapeutic window of application.
Authors: Gregg C Fonarow; Eric E Smith; Jeffrey L Saver; Mathew J Reeves; Deepak L Bhatt; Maria V Grau-Sepulveda; DaiWai M Olson; Adrian F Hernandez; Eric D Peterson; Lee H Schwamm Journal: Circulation Date: 2011-02-10 Impact factor: 29.690
Authors: Louis R Caplan; Juan Arenillas; Steven C Cramer; Anne Joutel; Eng H Lo; James Meschia; Sean Savitz; Elizabeth Tournier-Lasserve Journal: Arch Neurol Date: 2011-05-09
Authors: Giuseppe Castellano; Rita Melchiorre; Antonia Loverre; Pasquale Ditonno; Vincenzo Montinaro; Michele Rossini; Chiara Divella; Michele Battaglia; Giuseppe Lucarelli; Gennaro Annunziata; Silvano Palazzo; Francesco Paolo Selvaggi; Francesco Staffieri; Antonio Crovace; Mohamed R Daha; Maurice Mannesse; Sandra van Wetering; Francesco Paolo Schena; Giuseppe Grandaliano Journal: Am J Pathol Date: 2010-02-11 Impact factor: 4.307
Authors: P van der Pol; N Schlagwein; D J van Gijlswijk; S P Berger; A Roos; I M Bajema; H C de Boer; J W de Fijter; G L Stahl; M R Daha; C van Kooten Journal: Am J Transplant Date: 2012-01-06 Impact factor: 8.086
Authors: Melanie L Hart; Kathleen A Ceonzo; Lisa A Shaffer; Kazue Takahashi; Russell P Rother; Wende R Reenstra; Jon A Buras; Gregory L Stahl Journal: J Immunol Date: 2005-05-15 Impact factor: 5.422
Authors: M G De Simoni; C Storini; M Barba; L Catapano; A M Arabia; E Rossi; L Bergamaschini Journal: J Cereb Blood Flow Metab Date: 2003-02 Impact factor: 6.200
Authors: Nadine Heydenreich; Marc W Nolte; Eva Göb; Friederike Langhauser; Marion Hofmeister; Peter Kraft; Christiane Albert-Weissenberger; Marc Brede; Csanad Varallyay; Kerstin Göbel; Sven G Meuth; Bernhard Nieswandt; Gerhard Dickneite; Guido Stoll; Christoph Kleinschnitz Journal: Stroke Date: 2012-06-28 Impact factor: 7.914
Authors: Charlotte B Holt; Steffen Thiel; Kim Munk; Jakob A Østergaard; Hans E Bøtker; Troels K Hansen Journal: Eur Heart J Acute Cardiovasc Care Date: 2013-09-30
Authors: Erin A S Clark; Steven J Weiner; Dwight J Rouse; Brian M Mercer; Uma M Reddy; Jay D Iams; Ronald J Wapner; Yoram Sorokin; Fergal D Malone; Mary J O'Sullivan; Alan M Peaceman; Gary D V Hankins; Donald J Dudley; Steve N Caritis Journal: Am J Perinatol Date: 2018-03-06 Impact factor: 1.862
Authors: Vasile I Pavlov; Ying S Tan; Erin E McClure; Laura R La Bonte; Chenhui Zou; William B Gorsuch; Gregory L Stahl Journal: Am J Pathol Date: 2014-12-04 Impact factor: 4.307
Authors: Daniel Seung Kim; Yatong K Li; Jerry H Kim; Curtis S Bergquist; Marsha Gerdes; Judy C Bernbaum; Nancy Burnham; Donna M McDonald-McGinn; Elaine H Zackai; Susan C Nicolson; Thomas L Spray; Deborah A Nickerson; Hakon Hakonarson; Gail P Jarvik; J William Gaynor Journal: J Thorac Cardiovasc Surg Date: 2017-12-07 Impact factor: 5.209
Authors: V Frauenknecht; S Thiel; L Storm; N Meier; M Arnold; J-P Schmid; H Saner; V Schroeder Journal: Clin Exp Immunol Date: 2013-07 Impact factor: 4.330